Literature DB >> 17692976

Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity.

Valérie Fonteyne1, Wilfried De Neve, Geert Villeirs, Carlos De Wagter, Gert De Meerleer.   

Abstract

PURPOSE: To report on: 1. Late radiotherapy-induced lower intestinal toxicity (RILIT) after intensity-modulated radiotherapy (IMRT) for prostate cancer. 2. The correlation between late RILIT and volume parameters of the rectum, sigmoid colon and small bowel.
MATERIALS AND METHODS: We included 241 patients with a follow-up of >or=18 months for this analysis. Late RILIT consisted of 8 different symptoms, comprising the 5 symptoms from the RTOG toxicity score supplemented with urgency, fecal incontinence and anal pain. Late RILIT and late RTOG toxicity were scored prospectively and correlated with: 1. Different rectum, sigmoid colon and small bowel volume parameters. 2. Patient-related morbidity. We calculated the median, quartile and percentiles for the different volume parameters and correlated them with grade 1-3 late RILIT.
RESULTS: Median follow-up was 42 months. Three patients developed grade 3 red blood loss. We registered grade 2 RILIT and RTOG toxicity in 13% and 10%, respectively, the most frequent grade 1 symptom being fecal urgency. The intermediate rectal volume parameters were significantly correlated with late RILIT. We were able to calculate cut-off dose-volume histograms (DVHs) that predict for grade 0-2 RILIT.
CONCLUSIONS: After IMRT for prostate cancer, the overall incidence of grade >or=2 RILIT is low. Cut-off DVHs can be used for patient counseling.

Entities:  

Mesh:

Year:  2007        PMID: 17692976     DOI: 10.1016/j.radonc.2007.06.013

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

Review 1.  Evolution of advanced technologies in prostate cancer radiotherapy.

Authors:  Nicholas G Zaorsky; Amy S Harrison; Edouard J Trabulsi; Leonard G Gomella; Timothy N Showalter; Mark D Hurwitz; Adam P Dicker; Robert B Den
Journal:  Nat Rev Urol       Date:  2013-09-10       Impact factor: 14.432

2.  The contribution of the cone beam Kv CT (CBKvCT) to the reduction in toxicity of prostate cancer treatment with external 3D radiotherapy.

Authors:  Antonio José Conde-Moreno; Carlos Ferrer-Albiach; Mercedes Zabaleta-Meri; Xavi J Juan-Senabre; Agustín Santos-Serra
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

Review 3.  Gastrointestinal toxicity associated to radiation therapy.

Authors:  Mario López Rodríguez; Margarita Martín Martín; Laura Cerezo Padellano; Alicia Marín Palomo; Yamile Ibáñez Puebla
Journal:  Clin Transl Oncol       Date:  2010-08       Impact factor: 3.405

4.  Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome.

Authors:  K Vandecasteele; A Makar; R Van den Broecke; L Delrue; H Denys; K Lambein; B Lambert; M van Eijkeren; P Tummers; G De Meerleer
Journal:  Strahlenther Onkol       Date:  2012-04-19       Impact factor: 3.621

5.  Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation.

Authors:  Katrien Vandecasteele; Wilfried De Neve; Werner De Gersem; Louke Delrue; Leen Paelinck; Amin Makar; Valérie Fonteyne; Carlos De Wagter; Geert Villeirs; Gert De Meerleer
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

Review 6.  Reducing rectal injury during external beam radiotherapy for prostate cancer.

Authors:  Riccardo Valdagni; Tiziana Rancati
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

7.  Impact of late anorectal dysfunction on quality of life after pelvic radiotherapy.

Authors:  Robin Krol; Robert Jan Smeenk; Emile N J T van Lin; Wim P M Hopman
Journal:  Int J Colorectal Dis       Date:  2012-10-19       Impact factor: 2.571

8.  Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer.

Authors:  Valérie Fonteyne; Nicolaas Lumen; Geert Villeirs; Piet Ost; Gert De Meerleer
Journal:  Adv Urol       Date:  2011-11-30

Review 9.  Chronic radiation proctitis: tricks to prevent and treat.

Authors:  Ben G L Vanneste; Lien Van De Voorde; Rogier J de Ridder; Evert J Van Limbergen; Philippe Lambin; Emile N van Lin
Journal:  Int J Colorectal Dis       Date:  2015-07-23       Impact factor: 2.571

10.  Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre.

Authors:  Joseph Sia; Daryl Lim Joon; Angela Viotto; Carmel Mantle; George Quong; Aldo Rolfo; Morikatsu Wada; Nigel Anderson; Maureen Rolfo; Vincent Khoo
Journal:  Cancers (Basel)       Date:  2011-09-01       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.